{"id":5667,"date":"2017-03-28T20:07:43","date_gmt":"2017-03-29T00:07:43","guid":{"rendered":"http:\/\/localhost:10028\/practiceareas\/invokana\/"},"modified":"2022-06-21T16:54:04","modified_gmt":"2022-06-21T20:54:04","slug":"invokana","status":"publish","type":"practiceareas","link":"https:\/\/napolilaw.lemonadestand.org\/tr\/uygulama-alanlari-2\/invokana\/","title":{"rendered":"New York Invokana Avukatlar\u0131"},"content":{"rendered":"

ARTIK INVOKANA VAKALARINI KABUL ETM\u0130YORUZ<\/h2>\n

Invokana'n\u0131n arkas\u0131ndaki hikaye Januvia, Accutane, Byetta ve di\u011ferlerine \u00e7ok benzer. tehlikeli ila\u00e7lar<\/a>.<\/p>\n

Millions of Americans suffer from Type 2 Diabetes. As the disease spread in the early 2000s, anti-diabetes drugs were at a premium. So, when Invokana (Canagliflozin) became available in 2013, many people hailed it as a miracle drug. Janssen Pharmaceuticals Johnson & Johnson division, aggressively marketed Invokana as a cutting-edge way to control diabetes and lose weight. Before long, the company had sold billions of dollars worth of Invokana worldwide.<\/p>\n

But along the way, it appears that the company took dangerous shortcuts. In 2015, the Food and Drug Administration warned of possible serious complications, including diabetic ketoacidosis, bone fractures, and urinary tract infections. Later warnings included possible amputations and, in August 2018, Fournier\u2019s Gangrene. As a result, Invokana sales have tumbled almost 30 percent, and Janssen faces some 1,100 liability lawsuits.<\/p>\n

These lawsuits seek compensation for actual losses, as well as punitive damages. The complex legal and factual issues involved demand highly-experienced representation. The professional team at Napoli Hukuku<\/a> bu davalar\u0131 ele almak i\u00e7in kimlik bilgilerine sahiptir. Tehlikeli uyu\u015fturucular\u0131n kurbanlar\u0131n\u0131 \u00fclke \u00e7ap\u0131nda temsil ediyoruz, dolay\u0131s\u0131yla bu davalar\u0131n gerektirdi\u011fi kaynaklara sahibiz. Daha da \u00f6nemlisi, b\u00fcy\u00fck ila\u00e7 firmalar\u0131 Paul J. Napoli ve meslekta\u015flar\u0131n\u0131 korkutmuyor. Geri ad\u0131m atmayacaklar. Bunun yerine, hak etti\u011finiz tazminat\u0131 ve adaleti almak i\u00e7in sonuna kadar sava\u015facaklar.<\/p>\n

 <\/p>\n

Invokana Tehlikeli Bir \u0130la\u00e7 m\u0131?<\/h2>\n

Doctors were excited about Invokana because it inhibited subtype 2 sodium-glucose transport proteins. After several years of success in Europe, Canagliflozin was the first FDA-approved SGLT2 inhibitor.<\/p>\n

SGLT2 proteins reabsorb about 90 percent of the body\u2019s glucose. Invokana blocks these transporters, enabling patients to pass over 100 grams of blood sugar per day through their urine. That means the excess blood sugar never enters the kidneys.<\/p>\n

As a bonus, SGLT2 inhibitors, a class which also includes Xigduo XR, Qtern, Jardiance, Glyxambi, Synjardy, Invokamet, Invokamet XR, Farxiga, Synjardy XR, Steglatro, Segluromet and Steglujan, carry a very low risk of hypoglycemia (low blood sugar).<\/p>\n

Issues with the drug approval system magnified problems with the drug itself. It costs an average of $2.5 billion just to bring a new drug to market. At the same time, Congress has slashed the length of drug patents. So, companies like Janssen must sell a lot of product in a short amount of time to show a healthy profit. They aggressively market these drugs and sometimes bury negative information.<\/p>\n

bu Kemik Grefti \u0130nf\u00fczyonu<\/a> is a good example of an aggressive marketing campaign that went off the rails. To boost sales, Medtronic encouraged doctors to use the drug in experimental ways. The company sponsored lavish retreats for doctors and may have even falsified safety information.<\/p>\n

As for Invokana, Janssen was not able to bury negative information for long. It soon came to light, but not before this dangerous drug seriously injured thousands of patients.<\/p>\n

 <\/p>\n

Invokana Yan Etkileri, Birinci Tur<\/h2>\n

At the onset, Janssen acknowledged that Canagliflozin was risky. However, the company insisted that side effects were generally mild to moderate. They included things like thirst, high cholesterol levels, low blood pressure, and increased urination.<\/p>\n

But the company did not tell patients the whole story. It put profits before people. In 2015, the FDA issued warnings for:<\/p>\n

 <\/p>\n